AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06312800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Randomized allocation of treatments will guide the dispensation of treatments in one of 6 possible sequences--ex, M (methazolamide)- P(placebo)-A (Acamprosate); or PAM or MAP or PMA or AMP or APM. Biostatistician will devise medication randomization strategies and investigators and staff will be blinded.
Study NCT06312800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methazolamide
Description: Randomized allocation of treatments will guide the dispensation of treatments in one of 6 possible sequences--ex, M (methazolamide)- P(placebo)-A (Acamprosate); or PAM or MAP or PMA or AMP or APM. Biostatistician will devise medication randomization strategies and investigators and staff will be blinded.
Study NCT02688933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HOE901-U300 (Insulin Glargine 300 U/ml)
Description: Self-administered by subcutaneous (SC) injection in the morning (between waking up and breakfast) using a pre-filled pen.
Study NCT02688933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus (Insulin Glargine 100 U/ml)
Description: Self-administered by subcutaneous (SC) injection in the morning (between waking up and breakfast using a pre-filled pen.
Study NCT02688933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mandated back ground therapy
Description: Rapid insulin analogs: e.g., insulin glulisine, insulin lispro or insulin aspart, used by participant at least 30 days before screening. Mealtime insulin was to be continued during the study and titrated towards protocol specified postprandial glucose targets (130-180 mg/dL).
Study NCT02688933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mandated back ground therapy
Description: Rapid insulin analogs: e.g., insulin glulisine, insulin lispro or insulin aspart, used by participant at least 30 days before screening. Mealtime insulin was to be continued during the study and titrated towards protocol specified postprandial glucose targets (130-180 mg/dL).
Study NCT00828113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: Extension of 1 mg twice daily treatment to 52 weeks
Study NCT00828113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline
Description: Extension of 1 mg twice daily treatment to 52 weeks
Study NCT00828113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: Double-blind switch to placebo after 12 weeks of open-label therapy
Study NCT03917862 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: TDM-621
Description: The TDM-621 is a topic hemostatic product which will be used during ascending aortic surgery.
Study NCT00557908 — intervention group
Intervention type: DRUG
Intervention: VWF/FVIII products
Description: Participants in the prospective phase of the study undergo an escalation of treatment from receipt of one to three levels of VWD product. All subjects enrolled will begin treatment on the level one and remain on this regimen for the duration of follow-up, or until they meet the criteria for escalation to level two or three (if indeed they do meet the criteria.)~Dosing for joint bleeding, epistaxis, and GI bleeding indications: 50 U RCo/kg once per week, 50 U RCo/kg twice per week, or 50 U RCo/kg three times per week.~Dosing for menorrhagia: 50 U RCo/kg on day 1 of menses for 2 cycles, 50 U RCo/kg on days 1 and 2 of menses for 2 cycles, or 50 U RCo/kg on days 1, 2, and 3 of menses
Study NCT04523428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax/Acalabrutinib
Description: All patients will receive a lead-in with 2 cycles of acalabrutinib 100 mg bid. Hereafter patients will continue with ramp-up of venetoclax followed by daily 400 mg venetoclax in combination with acalabrutinib for 24 cycles. Patients will be treated until they have received a total of 26 cycles or until progression, whichever comes first.
Study NCT00600327 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoTex™ NexStent™
Description: EndoTex™ NexStent™ is a flexible, fine mesh Nitinol stent used to treat patients that are at high risk of adverse events from carotid endarterectomy and require carotid revascularization of a target vessel that has a reference diameter between 4mm and 9mm and stenosis that is less than 30mm in length.
Study NCT00600327 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filter Wire EZ™
Description: EPI Fliter Wire EZ™ Embolic Protection System is indicated for use as a guide wire and embolic protection system to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in coronary saphenous vein bypass grafts and carotid arteries.
Study NCT05396651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low fodmap diet
Description: elimination of high fodmap diet - High FODMAP diet: ice cream, soft cheese , yoghurt, cabbage , cauliflower, green bean, garlic, okra, onions, snow peas, broccoli, avocado , apple, mango , dates, watermelon, legumes , pulses, wheat , pasta , artificial sweeteners
Study NCT05396651 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NICE guidelines for IBS
Description: follow NICE guidelines for IBS :have regular meals and take time to eat. avoid missing meals or leaving long gaps between eating. drink at least 8 cups of fluid per day, especially water or other non-caffeinated drinks, for example herbal teas.~restrict tea and coffee to 3 cups per day. reduce intake of alcohol and fizzy drinks.
Study NCT00725270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: 600 mg of mifepristone
Study NCT00725270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo comparator
Study NCT03283475 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thigh lift
Description: liposuction-assisted medial avulsion thighplasty enables technically refined contouring of the thigh and the possible preservation of the local microvasculature, which results in reduced complication rates
Study NCT00685139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide 100 mg Capsule
Description: 100 mg capsule administered after an overnight fast.
Study NCT00685139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide (Zonegran®) 100 mg Capsule
Description: 100 mg capsule administered after an overnight fast.
Study NCT04467918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Already described
Study NCT04467918 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Already described
Study NCT01202149 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elidel (pimecrolimus cream, 1%) Hylatopic Plus Emollient Foam (non-medicated device)
Study NCT01978951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Chronic Kidney Disease care
Description: Activities of integrated CKD care program, which will be provided during each hospital visit and quarterly home visits, are live demonstration about treatment and optimal diets for CKD patients, monitor drug compliance.
Study NCT01978951 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional CKD care
Description: group counselling about optimal diets for CKD patients
Study NCT00167804 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Virtual Reality Exposure
Description: VRE uses computer generated environments to conduct exposure therapy.
Study NCT03143647 — intervention group
Intervention type: OTHER
Intervention: Collect a study-specific blood sample of healthy subjects
Description: One heparin tube (4ml) and one hirudin tube (4ml) blood sample will be collected through standard venipuncture. After applying a tourniquet with moderate pressure around the arm of the patient's choice, skin will be disinfected over a suitable vein in the elbow or fore-arm. A hirudin and a heparin tube will be filled with venous blood through a single puncture with a 22 Ga needle (manufacturer, location). After release of the tourniquet, bleeding will be stopped by applying local pressure for 5 minutes with a sterile gauze.
Study NCT01532804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab, oxaliplatin and 5FU combination
Description: Bevacizumab 5 mg/kg administered as an iv infusion for 1h30, then for 1h and for 30 min. at the following cycles, respectively.~Oxaliplatin 85 mg/m² administered as an iv infusion for 2h Elvorine 200 mg/m² administered as an iv infusion for 2h 5FU 400 mg/m2 bolus then 5FU 2,400 mg/m² iv infusion for 46h D1=D15 (12 cycles)
Study NCT01532804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab, oxaliplatin and raltitrexed combination
Description: Bevacizumab 7.5 mg/kg administered as an iv infusion for 1h30, then administered for 1h and 30 min at the following cycles, respectively.~Oxaliplatin 130 mg/m² administered as an iv infusion for 2h Raltitrexed 3 mg/m² administered as an iv infusion for 15 min
Study NCT00506246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: * intravenous (total intravenous anaesthesia)~* induction and maintenance
Study NCT00506246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: * intravenous (total intravenous anaesthesia)~* induction and maintenance
Study NCT00089960 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AMG 706
Description: AMG 706 125 mg daily for 48 weeks, or until progressive disease or unacceptable toxicity.
Study NCT03523026 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: Neuromuscular Electrical Stimulation(NMES) to rectus abdominis will be applied using 4 carbon silicon electrode. In the first sessions, patients ECG will be checked. Patients will be in semi-fowler position (30º),with their lower limbs to be in extension and upper limbs at their sides. The NMES frequency will be at 30 Hertz and the application time will be 30 minutes. Treatment will be programmed for 3 days per week. The patients will coordinate their breath (inspiration) with the contraction which will be generated by the electrical current. The program will continue for 6 weeks.
Study NCT03523026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspirator Muscle Training
Description: Inspirator Muscle Training(IMT) will be applied 7 days per week, twice a day for 15 minutes. The program will continue for 6 weeks duration under weekly control of the investigator.Training intensity will set at 30% of the maximum inspiratory pressure.
Study NCT03523026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral Muscle Training
Description: Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week.The program will continue for 6 weeks.
Study NCT04223804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-181
Description: Intravenous (IV) Infusion
Study NCT04223804 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous (IV) infusion
Study NCT03236623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menthol Popsicle
Description: The menthol popsicle composed of 0.05% menthol, 0.05% saccharin, 30ml ultrafiltered water and 2% cereal alcohol. The popsicle will have a support that will assist the patient in the administration of the intervention, giving him autonomy and safety in the application of the intervention.
Study NCT02456519 — intervention group
Intervention type: OTHER
Intervention: PaedQoR-15 questionnaire
Description: Children/ young people and one parent/ guardian will complete the questionnaire before and after general anaesthesia for surgery or diagnostic imaging.
Study NCT02993406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bempedoic acid 180 mg tablet
Description: Patients take bempedoic acid 180 mg tablet orally once daily
Study NCT02993406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo tablet
Description: Patients take matching placebo tablet orally once daily
Study NCT04829097 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: The patient received neoadjuvant temozolomide combined with simultaneous increase in intensity-modulated radiotherapy. According to data from previous clinical trials, neoadjuvant temozolomide combined with concurrently increased intensity-modulated radiotherapy PFS for 13.7 months.
Study NCT04829097 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: The patient received neoadjuvant temozolomide combined with simultaneous increase in intensity-modulated radiotherapy. According to data from previous clinical trials, neoadjuvant temozolomide combined with concurrently increased intensity-modulated radiotherapy PFS for 13.7 months.
Study NCT02919215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teacher Help Intervention
Description: The intervention will be provided to collaborating psychologists and their teachers to access. Teachers will work through the intervention, and psychologists will act as the online support for teachers. Teachers will work with one student in their classroom with ADHD, ASD, or LD throughout the intervention phase. Each session in the program will provide factual information to teachers, strategies for implementation of best practices to address the specific mental health disorder in the classroom setting (i.e., ADHD, ASD, or LD), and access to additional help and advice.
Study NCT03076073 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Impact of physical activity on tendons
Description: Single vs. multiple (up to 12 weeks) of different types of physical exercises (aerobic vs. anaerobic activities).
Study NCT03412851 — intervention group
Intervention type: OTHER
Intervention: A Direct Aspiration First Pass Technique
Description: Distal aspiration technique
Study NCT03412851 — intervention group
Intervention type: OTHER
Intervention: Stentriever Thrombectomy
Description: Thrombectomy with stent retriever
Study NCT01365936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HMG
Description: In this prospective trial, women with PCOS (according to Rotterdam criteria) were randomized (80 patients) after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
Study NCT01365936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rFSH
Description: Patients were randomized after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
Study NCT04442100 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: valve prosthetics
Description: prosthetics of heart valves with dentures MedEng-Bio
Study NCT04496245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Broncho-Vaxom®
Description: Broncho-Vaxom adult capsules® (OM85)
Study NCT04496245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Broncho-Vaxom®
Description: Broncho-Vaxom adult capsules® (OM85)
Study NCT00828113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline
Description: Double-blind switch to placebo after 12 weeks of open-label therapy
Study NCT00828113 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual smoking cessation counseling
Description: Brief (\<10 minutes) smoking cessation counseling delivered at clinic visits
Study NCT00828113 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual smoking cessation counseling
Description: Brief (\<10 minutes) smoking cessation counseling delivered at clinic visits
Study NCT05588986 — intervention group
Intervention type: OTHER
Intervention: ultrasonography
Description: Umbilical artery Doppler evaluation by ultrasonography just before the first dose of antenatal corticosteroid, 24 hours and 48 hours after the last dose.
Study NCT01963884 — intervention group
Intervention type: PROCEDURE
Intervention: Tooth Extraction
Description: Tooth from the maxillary anterior area extracted and alveolar socket remains intact
Study NCT01963884 — intervention group
Intervention type: RADIATION
Intervention: Cone-Beam technology evaluation
Description: Patient is submitted to a localized cone-beam image before tooth extraction and 6 month later, prior to implant installation.
Study NCT01963884 — intervention group
Intervention type: OTHER
Intervention: Measure Alveolar Socket Remodeling
Description: In a computer, cone-beam images are superimposed to measure total the amount of ridge dimension
Study NCT04296708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergame Training
Description: An exergame combines exercise and gaming in a holistic approach.
Study NCT03183115 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: HALO360 System (Covidien GI Solutions, Sunnyvale, California, USA), which has been approved by the US Food and Drug Administration (FDA) and is approved for use in Europe (CE mark) and Taiwan (Ministry of Health and Welfare). Because the HALO 360 balloon catheter has been phased out since 2019, a new Barrx™ 360 Express catheter was used thereafter.
Study NCT03183115 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopy
Description: The participants will receive meticulous endoscopic examination with Lugol chromoendoscopy and Narrow-band imaging
Study NCT03183115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lugol's Solution (1.5%)
Description: Before the RFA intervention, the participants will received Lugol staining over the esophagus
Study NCT01136252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Intravitreal adalimumab injection (0,1 ml= 50 mcg) in the eye of the included patients. Patients will be followed up every week for a total of 4 weeks, and after every month until 6 months. If it is necessary, repeat the injection every month, maximum three months
Study NCT01121939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg IV Day 1. The first dose should be administered over~90 minutes. If no adverse reactions occur after the initial dose, the second dose should~be administered over a minimum of 60 minutes. If no adverse reactions occur after the~second dose, all subsequent doses should be administered over a minimum of 30~minutes. Bevacizumab will be infused prior to pertuzumab.
Study NCT01121939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 840 mg IV loading dose infused over 60 minutes. The loading dose is given on Cycle 1, Day 1 or as below. Subsequent doses of pertuzumab are 420 mg IV. If the patient tolerates the initial infusion over 60 minutes, the patient may receive subsequent infusions over 30 minutes. Otherwise, pertuzumab should be infused over 60 minutes. Patients should be observed for 30 minutes after completing the pertuzumab infusion.~If a patient misses a dose of pertuzumab for 1 cycle (i.e., 2 sequential cycles or administrations are 6 weeks or more apart), a re-loading dose (840 mg) of pertuzumab should be given. If re-loading pertuzumab is administered, subsequent doses of 420 mg will then be given every 3 weeks, starting 3 weeks later.
Study NCT01121939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sandostatin LAR® Depot
Description: 30 mg will be given every 28 days by IM injection. The dose of sandostatin may be increased, at the discretion of the treating physician, if necessary to control symptoms related to tumor secretion of vasoactive peptides.
Study NCT03974282 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychological task
Description: Participants will complete a psychological task that evokes antisocially- and prosocially-motivated empathic responding
Study NCT01228318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zoledronic acid
Description: 1. A single dose of reclast containing 5 mg/100 mL ready-to-infuse zoledronic acid solution administered over 15-30 minutes.~2. A single dose of placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution, administered over 15-30 minutes.
Study NCT01228318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: 1. A single dose of reclast containing 5 mg/100 mL ready-to-infuse zoledronic acid solution administered over 15-30 minutes.~2. A single dose of placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution, administered over 15-30 minutes.
Study NCT02298426 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Management
Description: We provide large scales of weight management information included recipes according to people's constitution. Information is provide through both face to face meeting and telephones. Materials are also given to participants.
Study NCT02298426 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General Management
Description: We provide general information about health. Information is provided through telephones and materials.
Study NCT02298426 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General Management
Description: We provide general information about health. Information is provided through telephones and materials.
Study NCT02298426 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: We use placebo to replace the health product.
Study NCT02298426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: We use placebo to replace the health product.